Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gen Sobue

Showing results (491-500 of 576) with videos related to

Pageof 58
Sort By:
Plos One|January 6, 2018
Severe hyposmia and aberrant functional connectivity in cognitively normal Parkinson's diseaseNoritaka Yoneyama, Hirohisa Watanabe, Kazuya Kawabata, et al.
European Journal of Neurology|February 7, 2022
Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosisKensuke Ikenaka, Yasuhiro Maeda, Yuji Hotta, et al.
Nagoya Journal of Medical Science|September 23, 2021
A case of sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance: long-term observation of neurological symptoms after autologous stem-cell transplantationTakashi Ando, Takahiko Sato, Shingo Kurahashi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 4, 2017
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trialSatoshi Kuwabara, Masahiro Mori, Sonoko Misawa, et al.
Neuroscience Research|December 6, 2025
The TDP-43<sup>I383V</sup> heterozygous mutation results in increased TDP-43 expression and altered neuronal activity in ALS patient-derived iPSC motor neuronsRyo Chikuchi, Yuta Kato, Aya Tomatsu, et al.
Annals of Nuclear Medicine|May 10, 2023
Comparative examination of the pons and corpus callosum as reference regions for quantitative evaluation in positron emission tomography imaging for Alzheimer's disease using <sup>11</sup>C-Pittsburgh Compound-BTomohiro Tada, Kazuhiro Hara, Naotoshi Fujita, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 12, 2020
Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndromeYuko Yamagishi, Motoi Kuwahara, Hidekazu Suzuki, et al.
Nature Communications|September 21, 2019
Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophyMadoka Iida, Kentaro Sahashi, Naohide Kondo, et al.
Muscle & Nerve|June 6, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)Jeffrey Rothstein, Angela Genge, Shari De Silva, et al.
Muscle & Nerve|December 23, 2025
Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral SclerosisAngela Genge, Jeffrey Rothstein, Shari De Silva, et al.
Pageof 58

Showing results (491-500 of 576) with videos related to

Sort By:
Pageof 58
Plos One|January 6, 2018
Severe hyposmia and aberrant functional connectivity in cognitively normal Parkinson's diseaseNoritaka Yoneyama, Hirohisa Watanabe, Kazuya Kawabata, et al.
European Journal of Neurology|February 7, 2022
Serum asymmetric dimethylarginine level correlates with the progression and prognosis of amyotrophic lateral sclerosisKensuke Ikenaka, Yasuhiro Maeda, Yuji Hotta, et al.
Nagoya Journal of Medical Science|September 23, 2021
A case of sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance: long-term observation of neurological symptoms after autologous stem-cell transplantationTakashi Ando, Takahiko Sato, Shingo Kurahashi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 4, 2017
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trialSatoshi Kuwabara, Masahiro Mori, Sonoko Misawa, et al.
Neuroscience Research|December 6, 2025
The TDP-43<sup>I383V</sup> heterozygous mutation results in increased TDP-43 expression and altered neuronal activity in ALS patient-derived iPSC motor neuronsRyo Chikuchi, Yuta Kato, Aya Tomatsu, et al.
Annals of Nuclear Medicine|May 10, 2023
Comparative examination of the pons and corpus callosum as reference regions for quantitative evaluation in positron emission tomography imaging for Alzheimer's disease using <sup>11</sup>C-Pittsburgh Compound-BTomohiro Tada, Kazuhiro Hara, Naotoshi Fujita, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 12, 2020
Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndromeYuko Yamagishi, Motoi Kuwahara, Hidekazu Suzuki, et al.
Nature Communications|September 21, 2019
Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophyMadoka Iida, Kentaro Sahashi, Naohide Kondo, et al.
Muscle & Nerve|June 6, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)Jeffrey Rothstein, Angela Genge, Shari De Silva, et al.
Muscle & Nerve|December 23, 2025
Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral SclerosisAngela Genge, Jeffrey Rothstein, Shari De Silva, et al.
Pageof 58